Kura Oncology (NASDAQ:KURA) CEO Buys $750,302.98 in Stock

Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) CEO Troy Wilson bought 101,119 shares of Kura Oncology stock in a transaction that occurred on Monday, November 16th. The stock was bought at an average price of $7.42 per share, with a total value of $750,302.98. Following the completion of the acquisition, the chief executive officer owned 635,456 shares in the company, valued at approximately $4,715,083.52. The trade was a 18.92% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Troy Edward Wilson also recently made the following trade(s):

  • On Friday, November 13th, Troy Wilson bought 98,881 shares of Kura Oncology stock. The shares were acquired at an average price of $7.63 per share, for a total transaction of $754,462.03.
  • On Monday, August 24th, Troy Wilson bought 100,000 shares of Kura Oncology stock. The stock was purchased at an average price of $12.39 per share, for a total transaction of $1,239,000.00.

Kura Oncology Price Performance

KURA stock opened at $7.34 on Thursday. The business’s 50 day simple moving average is $9.85 and its 200 day simple moving average is $9.75. Kura Oncology, Inc. has a 1-year low of $6.75 and a 1-year high of $13.90. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.60 and a quick ratio of 3.56.

Kura Oncology (NASDAQ:KURA – Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.78) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.04. Kura Oncology had a negative net margin of 369.26% and a negative return on equity of 336.24%. The company had revenue of $22.84 million during the quarter, compared to analyst estimates of $24.94 million. As a group, analysts expect that Kura Oncology, Inc. will post -3.20 EPS for the current fiscal year.

Institutional Trading of Kura Oncology

Several institutional investors have recently made changes to their positions in the business. BlackRock Inc. bought a new position in Kura Oncology in the second quarter valued at approximately $115,286,000. Dimensional Fund Advisors LP increased its position in shares of Kura Oncology by 32.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company’s stock worth $11,591,000 after purchasing an additional 348,127 shares during the period. Algert Global LLC bought a new position in Kura Oncology in the third quarter valued at about $13,976,000. Bank of America Corp DE increased its holdings in Kura Oncology by 46.1% in the 1st quarter. Bank of America Corp DE now owns 1,230,131 shares of the company’s stock worth $10,001,000 after purchasing an additional 388,003 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Kura Oncology in the second quarter worth $10,927,000.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Citigroup reiterated a “market outperform” rating on shares of Kura Oncology in a research report on Thursday, November 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kura Oncology in a report on Thursday, October 15th. Wedbush increased their target price on shares of Kura Oncology from $36.00 to $38.00 and gave the company an “outperform” rating in a research report on Thursday, August 13th. Barclays set a $24.00 price objective on shares of Kura Oncology in a research report on Wednesday, October 14th. Finally, UBS Group set a $24.00 price target on Kura Oncology in a research report on Thursday, November 12th. Eleven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $25.88.

Get Our Latest Stock Report on Kura Oncology

About Kura Oncology

(Get Free Report)

Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company’s best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.

Featured Articles

Insider Buying and Selling by Quarter for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.